H. Lundbeck, early treatment with rasagiline may slow Parkinson’s disease impairment

As announced today by H. Lundbeck A/S’s partner Teva Pharmaceutical Industries Ltd., early initiation of a potential new treatment for Parkinson’s disease may delay the progression of impairment associated with the disease, according to an article published in the April 2004 issue of Archives of Neurology.